Related Experiment Video

Updated: Jun 13, 2025

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.8K

The m6A regulators in prostate cancer: molecular basis and clinical perspective

Yu Cao1, Man Jia1, Chunyan Duan1

  • 1Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southwest Medical University, Luzhou, China.

Frontiers in Pharmacology
|September 13, 2024
PubMed

Insights

This review summarizes how N6-Methyladenosine (m6A) regulators impact prostate cancer (PCa) development and interact with androgen receptor (AR) signaling. Understanding m6A regulators offers new insights into PCa progression and potential therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Prostate cancer (PCa) is a leading cause of cancer death in men, with androgen receptor (AR) signaling as a key driver.
  • AR-independent pathways also contribute to PCa progression, highlighting the need to explore other molecular mechanisms.
  • N6-Methyladenosine (m6A) modification of RNA plays a critical role in RNA metabolism and has emerged as a significant factor in various diseases, including PCa.

Purpose of the Study:

  • To comprehensively review the role of individual m6A regulators in prostate cancer development.
  • To elucidate the interaction between m6A signaling pathways and androgen receptor (AR) signaling in PCa.
  • To provide a detailed summary of upstream and downstream signaling pathways influenced by m6A regulators in PCa.

Main Methods:

  • Literature review focusing on m6A regulators and their involvement in prostate cancer.
  • Analysis of existing research on the interplay between m6A signaling and AR pathways.
  • Synthesis of information regarding the biological functions and clinical relevance of m6A regulators in PCa.

Main Results:

  • m6A regulators significantly influence prostate cancer progression through various mechanisms.
  • Interactions between m6A regulators and AR signaling pathways are crucial in dictating PCa development.
  • Specific m6A regulators show distinct roles in promoting or suppressing PCa, depending on the cellular context.

Conclusions:

  • m6A regulators represent a critical layer of gene regulation in prostate cancer.
  • Targeting m6A regulators may offer novel therapeutic strategies for PCa, potentially overcoming resistance to AR-targeted therapies.
  • Further research into m6A biology in PCa is essential for advancing clinical practice and improving patient outcomes.
Keywords:
N6-MethyladenosinePCaandrogen deprivation therapy (ADT)androgen receptersignaling pathway

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.8K
MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

24.5K

Related Concept Videos

Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
6.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.2K
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
6.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K